Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04023552
Other study ID # CTQJ230A12301
Secondary ID CTQJ230A12301201
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date December 12, 2019
Est. completion date May 30, 2025

Study information

Verified date November 2023
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 8323
Est. completion date May 30, 2025
Est. primary completion date May 29, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Key Inclusion Criteria - Lp(a) = 70 mg/dL at the screening visit, measured at the Central laboratory - Myocardial infarction: = 3 months from screening and randomization to = 10 years prior to the screening visit - Ischemic stroke: = 3 months from screening and randomization to = 10 years prior to the screening visit - Clinically significant symptomatic peripheral artery disease Key Exclusion Criteria - Uncontrolled hypertension - Heart failure New York Heart Association (NYHA) class IV - History of malignancy of any organ system - History of hemorrhagic stroke or other major bleeding - Platelet count =LLN - Active liver disease or hepatic dysfunction - Significant kidney disease - Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may apply at the end.

Study Design


Intervention

Drug:
TQJ230
TQJ230 80 mg injected monthly administered subcutaneously
Placebo
Placebo to match TQJ230 prefilled syringe to be injected subcutaneously

Locations

Country Name City State
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Caba
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Capital Federal
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Corrientes
Argentina Novartis Investigative Site Mar del Plata Buenos Aires
Argentina Novartis Investigative Site Ramos Mejia Buenos Aires
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site San Luis
Argentina Novartis Investigative Site San Miguel de Tucuman Tucuman
Argentina Novartis Investigative Site Santa Fe
Argentina Novartis Investigative Site Tucuman San Miguel De Tucuman
Australia Novartis Investigative Site Camperdown New South Wales
Australia Novartis Investigative Site Chemside Queensland
Australia Novartis Investigative Site Clayton Victoria
Australia Novartis Investigative Site Liverpool New South Wales
Australia Novartis Investigative Site Perth Western Australia
Australia Novartis Investigative Site Southport Queensland
Australia Novartis Investigative Site Woolloongabba Queensland
Austria Novartis Investigative Site Graz
Austria Novartis Investigative Site Innsbruck
Austria Novartis Investigative Site Linz
Austria Novartis Investigative Site Salzburg
Austria Novartis Investigative Site Wien
Austria Novartis Investigative Site Wien
Belgium Novartis Investigative Site Aalst
Belgium Novartis Investigative Site Brugge
Belgium Novartis Investigative Site Bruxelles
Belgium Novartis Investigative Site Dendermonde
Belgium Novartis Investigative Site Genk
Belgium Novartis Investigative Site Huy
Belgium Novartis Investigative Site Kortrijk
Belgium Novartis Investigative Site Mechelen
Brazil Novartis Investigative Site Aracaju SE
Brazil Novartis Investigative Site Belo Horizonte MG
Brazil Novartis Investigative Site Belo Horizonte MG
Brazil Novartis Investigative Site Blumenau Santa Catarina
Brazil Novartis Investigative Site Brasilia DF
Brazil Novartis Investigative Site Campinas SP
Brazil Novartis Investigative Site Campinas SP
Brazil Novartis Investigative Site Canoas RS
Brazil Novartis Investigative Site Curitiba Parana
Brazil Novartis Investigative Site Curitiba PR
Brazil Novartis Investigative Site Goiania GO
Brazil Novartis Investigative Site Juiz de Fora MG
Brazil Novartis Investigative Site Maceio AL
Brazil Novartis Investigative Site Porto Alegre RS
Brazil Novartis Investigative Site Porto Alegre RS
Brazil Novartis Investigative Site Ribeirao Preto SP
Brazil Novartis Investigative Site Rio de Janeiro
Brazil Novartis Investigative Site Salvador BA
Brazil Novartis Investigative Site Santo Andre SP
Brazil Novartis Investigative Site Santo Andre SP
Brazil Novartis Investigative Site Sao Jose do Rio Preto SP
Brazil Novartis Investigative Site Sao Jose do Rio Preto SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site Sao Paulo
Brazil Novartis Investigative Site Uberlandia Minas Gerais
Brazil Novartis Investigative Site Vitoria ES
Bulgaria Novartis Investigative Site Blagoevgrad
Bulgaria Novartis Investigative Site Burgas
Bulgaria Novartis Investigative Site Pernik
Bulgaria Novartis Investigative Site Pleven
Bulgaria Novartis Investigative Site Plovdiv
Bulgaria Novartis Investigative Site Ruse
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Canada Novartis Investigative Site Levis Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Oakville Ontario
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Sainte Foy Quebec
Canada Novartis Investigative Site Terrebonne Quebec
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Vancouver British Columbia
Canada Novartis Investigative Site Vancouver British Columbia
Canada Novartis Investigative Site Victoria British Columbia
Canada Novartis Investigative Site Victoria British Columbia
Chile Novartis Investigative Site Santiago Region Metropolitana
Chile Novartis Investigative Site Santiago RM
Chile Novartis Investigative Site Santiago RM
Chile Novartis Investigative Site Santiago
Chile Novartis Investigative Site Santiago
Chile Novartis Investigative Site Santiago
China Novartis Investigative Site Baotou Inner Mongolia
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Changchun Jilin
China Novartis Investigative Site Changsha Hunan
China Novartis Investigative Site Changsha Hunan
China Novartis Investigative Site Chengdu Sichuan
China Novartis Investigative Site Dalian Liaoning
China Novartis Investigative Site Foshan Guangdong
China Novartis Investigative Site Guangzhou Guangdong
China Novartis Investigative Site Guangzhou Guangdong
China Novartis Investigative Site Hangzhou Zhejiang
China Novartis Investigative Site Hangzhou Zhejiang
China Novartis Investigative Site Harbin Heilongjiang
China Novartis Investigative Site Jinan Shandong
China Novartis Investigative Site Lanzhou Gansu
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Nanjing
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Suzhou Jiangsu
China Novartis Investigative Site Tianjin Tianjin
China Novartis Investigative Site Tianjin
China Novartis Investigative Site Tianjin
China Novartis Investigative Site Wenzhou Zhejiang
China Novartis Investigative Site Wuhan Hubei
China Novartis Investigative Site Wulumuqi Xinjiang
China Novartis Investigative Site Xiamen
China Novartis Investigative Site Xian Shanxi
China Novartis Investigative Site Xuzhou Jiangsu
Colombia Novartis Investigative Site Barranquilla
Colombia Novartis Investigative Site Bogota
Colombia Novartis Investigative Site Bogota Cundinamarca
Colombia Novartis Investigative Site Bucaramanga Santander
Colombia Novartis Investigative Site Cali Valle Del Cauca
Colombia Novartis Investigative Site Cali Valle Del Cauca
Colombia Novartis Investigative Site Medellin Antioquia
Colombia Novartis Investigative Site Medellin
Colombia Novartis Investigative Site San Gil
Czechia Novartis Investigative Site Brandys nad Labem Czech Republic
Czechia Novartis Investigative Site Brno Czech Republic
Czechia Novartis Investigative Site Brno Czech Republic
Czechia Novartis Investigative Site Brno
Czechia Novartis Investigative Site Brno Bohunice
Czechia Novartis Investigative Site Broumov
Czechia Novartis Investigative Site Cesky Krumlov Czech Republic
Czechia Novartis Investigative Site Chlumec nad Cidlinou
Czechia Novartis Investigative Site CZE
Czechia Novartis Investigative Site Hlucin
Czechia Novartis Investigative Site Hodonin
Czechia Novartis Investigative Site JIhlava
Czechia Novartis Investigative Site Kolin
Czechia Novartis Investigative Site Kromeriz Czech Republic
Czechia Novartis Investigative Site Liberec
Czechia Novartis Investigative Site Liberec V Kristianova Czech Republic
Czechia Novartis Investigative Site Louny Czech Republic
Czechia Novartis Investigative Site Marianske lazne
Czechia Novartis Investigative Site Melnik
Czechia Novartis Investigative Site Most CZE
Czechia Novartis Investigative Site Olomouc
Czechia Novartis Investigative Site Ostrava
Czechia Novartis Investigative Site Ostrava
Czechia Novartis Investigative Site Ostrava
Czechia Novartis Investigative Site Ostrava Czech Republic
Czechia Novartis Investigative Site Pardubice Czech Republic
Czechia Novartis Investigative Site Policska CZE
Czechia Novartis Investigative Site Praha
Czechia Novartis Investigative Site Praha
Czechia Novartis Investigative Site Praha
Czechia Novartis Investigative Site Praha 5
Czechia Novartis Investigative Site Prerov
Czechia Novartis Investigative Site Slany
Czechia Novartis Investigative Site Svitavy Czech Republic
Czechia Novartis Investigative Site Trebic Czech Republic
Czechia Novartis Investigative Site Trutnov CZE
Czechia Novartis Investigative Site Uherske Hradiste
Czechia Novartis Investigative Site Usti nad Labem Czech Republic
Czechia Novartis Investigative Site Valasske Mezirici
Czechia Novartis Investigative Site Zlin
Denmark Novartis Investigative Site Aalborg
Denmark Novartis Investigative Site Arhus N
Denmark Novartis Investigative Site Esbjerg
Denmark Novartis Investigative Site Glostrup
Denmark Novartis Investigative Site Herlev
Denmark Novartis Investigative Site Roskilde
Denmark Novartis Investigative Site Viborg
France Novartis Investigative Site Bron
France Novartis Investigative Site Chambray les Tours
France Novartis Investigative Site Compiègne
France Novartis Investigative Site Grenoble Cedex 9
France Novartis Investigative Site Le Coudray
France Novartis Investigative Site Lille
France Novartis Investigative Site Paris
France Novartis Investigative Site Paris
France Novartis Investigative Site Paris
France Novartis Investigative Site St Herblain
France Novartis Investigative Site Toulouse 4
France Novartis Investigative Site Tourcoing
France Novartis Investigative Site Valenciennes
Germany Novartis Investigative Site Aachen
Germany Novartis Investigative Site Bad Gottleuba Sachsen
Germany Novartis Investigative Site Bad Homburg
Germany Novartis Investigative Site Bad Krozingen
Germany Novartis Investigative Site Bad Oeynhausen
Germany Novartis Investigative Site Bamberg
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Bielefeld
Germany Novartis Investigative Site Chemnitz
Germany Novartis Investigative Site Chemnitz Saxony
Germany Novartis Investigative Site Dessau-Roßlau
Germany Novartis Investigative Site Dortmund
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dresden Sachsen
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Gelnhausen
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hannover Niedersachsen
Germany Novartis Investigative Site Jena
Germany Novartis Investigative Site Kassel
Germany Novartis Investigative Site Koeln
Germany Novartis Investigative Site Koeln-Nippes
Germany Novartis Investigative Site Kuenzing
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Leipzig Sachsen
Germany Novartis Investigative Site Loehne
Germany Novartis Investigative Site Lüneburg
Germany Novartis Investigative Site Lutherstadt Wittenberg
Germany Novartis Investigative Site Magdeburg
Germany Novartis Investigative Site Mannheim
Germany Novartis Investigative Site Mannheim Baden Wuerttemberg
Germany Novartis Investigative Site Meißen
Germany Novartis Investigative Site Muehldorf
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Muenster
Germany Novartis Investigative Site Potsdam
Germany Novartis Investigative Site Rüdersdorf
Germany Novartis Investigative Site Saint Ingbert - Oberwuerzbach
Germany Novartis Investigative Site Ulm
Germany Novartis Investigative Site Warendorf
Germany Novartis Investigative Site Weiden
Greece Novartis Investigative Site Athens GR
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Chalkida
Greece Novartis Investigative Site Ioannina GR
Greece Novartis Investigative Site Larissa GR
Greece Novartis Investigative Site Thessaloniki
Guatemala Novartis Investigative Site Guatemala
Guatemala Novartis Investigative Site Guatemala
Guatemala Novartis Investigative Site Guatemala
Guatemala Novartis Investigative Site Guatemala City
Guatemala Novartis Investigative Site Guatemala City
Guatemala Novartis Investigative Site Guatemala City
Hong Kong Novartis Investigative Site Hong Kong
Hong Kong Novartis Investigative Site Hongkong
Hungary Novartis Investigative Site Baja
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest HUN
Hungary Novartis Investigative Site Debrecen
Hungary Novartis Investigative Site Kistarcsa
Hungary Novartis Investigative Site Mako
Hungary Novartis Investigative Site Mateszalka
Hungary Novartis Investigative Site Miskolc
Hungary Novartis Investigative Site Nyiregyhaza
Hungary Novartis Investigative Site Pecs Baranya
Hungary Novartis Investigative Site Pecs Baranya
Hungary Novartis Investigative Site Szeged
Hungary Novartis Investigative Site Szekesfehervar Fejer
Iceland Novartis Investigative Site Kopavogur
Iceland Novartis Investigative Site Reykjavik
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Ahmedabad Gujrat
India Novartis Investigative Site Belagavi
India Novartis Investigative Site Bengaluru Karnataka
India Novartis Investigative Site Bikaner Rajasthan
India Novartis Investigative Site Chennai Tamil Nadu
India Novartis Investigative Site Coimbatore Tamil Nadu
India Novartis Investigative Site Coimbatore
India Novartis Investigative Site DehraDun Uttarakhand
India Novartis Investigative Site Ghaziabad Uttar Pradesh
India Novartis Investigative Site Guntur Andhrapradesh
India Novartis Investigative Site Hyderabad Andhra Pradesh
India Novartis Investigative Site Hyderabad Telangana
India Novartis Investigative Site Hyderabad Telangana
India Novartis Investigative Site Kochi Kerala
India Novartis Investigative Site Kochi Kerala
India Novartis Investigative Site Kochi Kerala
India Novartis Investigative Site Kozhikode Kerala
India Novartis Investigative Site Lucknow Uttar Pradesh
India Novartis Investigative Site Mangalore Karnataka
India Novartis Investigative Site Manipal Karnataka
India Novartis Investigative Site Mumbai Maharashtra
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nashik Maharashtra
India Novartis Investigative Site New Delhi Delhi
India Novartis Investigative Site New Delhi
India Novartis Investigative Site New Delhi
India Novartis Investigative Site Pune Maharashtra
India Novartis Investigative Site Pune Maharashtra
India Novartis Investigative Site Pune Maharashtra
India Novartis Investigative Site Secunderabad Telangana
India Novartis Investigative Site Vadodara Gujarat
India Novartis Investigative Site Varanasi Uttar Pradesh
Israel Novartis Investigative Site Beer-Sheva
Israel Novartis Investigative Site Haifa
Israel Novartis Investigative Site Haifa
Israel Novartis Investigative Site Jerusalem
Israel Novartis Investigative Site Petach Tikva
Israel Novartis Investigative Site Ramat Gan
Israel Novartis Investigative Site Tel Giborim, Holon
Italy Novartis Investigative Site Ancona AN
Italy Novartis Investigative Site Bergamo BG
Italy Novartis Investigative Site Bologna BO
Italy Novartis Investigative Site Brescia BS
Italy Novartis Investigative Site Cona FE
Italy Novartis Investigative Site Firenze FI
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Napoli
Italy Novartis Investigative Site Palermo PA
Italy Novartis Investigative Site Perugia PG
Italy Novartis Investigative Site Pisa PI
Italy Novartis Investigative Site Pisa PI
Italy Novartis Investigative Site Pozzilli IS
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Rozzano MI
Italy Novartis Investigative Site Salerno SA
Italy Novartis Investigative Site Varese VA
Japan Novartis Investigative Site Asahi Chiba
Japan Novartis Investigative Site Bunkyo ku Tokyo
Japan Novartis Investigative Site Chuo ku Tokyo
Japan Novartis Investigative Site Chuo-ku Tokyo
Japan Novartis Investigative Site Fukuoka city Fukuoka
Japan Novartis Investigative Site Funabashi Chiba
Japan Novartis Investigative Site Hachioji-city Tokyo
Japan Novartis Investigative Site Hirosaki Aomori
Japan Novartis Investigative Site Itabashi-ku Tokyo
Japan Novartis Investigative Site Kahoku-gun Ishikawa
Japan Novartis Investigative Site Kanazawa-city Ishikawa
Japan Novartis Investigative Site Kawaguchi-city Saitama
Japan Novartis Investigative Site Kawasaki Kanagawa
Japan Novartis Investigative Site Kitakyushu-city Fukuoka
Japan Novartis Investigative Site Komatsu Ishikawa
Japan Novartis Investigative Site Kure-city Hiroshima
Japan Novartis Investigative Site Matsudo-city Chiba
Japan Novartis Investigative Site Miyhazaki-city Miyazaki
Japan Novartis Investigative Site Nagaoka-city Niigata
Japan Novartis Investigative Site Nagoya Aichi
Japan Novartis Investigative Site Ogaki-city Gifu
Japan Novartis Investigative Site Omihachiman Shiga
Japan Novartis Investigative Site Osaka city Osaka
Japan Novartis Investigative Site Osaka-city Osaka
Japan Novartis Investigative Site Ota-ku Tokyo
Japan Novartis Investigative Site Sagamihara Kanagawa
Japan Novartis Investigative Site Sayama-city Saitama
Japan Novartis Investigative Site Sendai city Miyagi
Japan Novartis Investigative Site Seto-city Aichi
Japan Novartis Investigative Site Shinagawa-ku Tokyo
Japan Novartis Investigative Site Takamatsu city Kagawa
Japan Novartis Investigative Site Toshima-ku Tokyo
Japan Novartis Investigative Site Tsuchiura Ibaraki
Japan Novartis Investigative Site Yokohama city Kanagawa
Japan Novartis Investigative Site Yokohama-city Kanagawa
Korea, Republic of Novartis Investigative Site Bundang Gu Gyeonggi Do
Korea, Republic of Novartis Investigative Site Busan
Korea, Republic of Novartis Investigative Site Daegu Dalseo Gu
Korea, Republic of Novartis Investigative Site Gwangju
Korea, Republic of Novartis Investigative Site Incheon
Korea, Republic of Novartis Investigative Site Seoul
Korea, Republic of Novartis Investigative Site Seoul
Korea, Republic of Novartis Investigative Site Seoul Korea
Korea, Republic of Novartis Investigative Site Seoul KOR
Korea, Republic of Novartis Investigative Site Seoul Seocho Gu
Korea, Republic of Novartis Investigative Site Suwon si Gyeonggi Do
Korea, Republic of Novartis Investigative Site Wonju Gangwon-Do
Mexico Novartis Investigative Site Aguascalientes
Mexico Novartis Investigative Site Cuernavaca Morelos
Mexico Novartis Investigative Site Culiacan Sinaloa
Mexico Novartis Investigative Site Distrito Federal
Mexico Novartis Investigative Site San Luis Potosi
Netherlands Novartis Investigative Site Alkmaar
Netherlands Novartis Investigative Site Amersfoort
Netherlands Novartis Investigative Site Amsterdam
Netherlands Novartis Investigative Site Amsterdam
Netherlands Novartis Investigative Site Apeldoorn DZ
Netherlands Novartis Investigative Site Arnhem Gelderland
Netherlands Novartis Investigative Site Delft
Netherlands Novartis Investigative Site Den Haag
Netherlands Novartis Investigative Site Deventer
Netherlands Novartis Investigative Site Enschede
Netherlands Novartis Investigative Site Gouda
Netherlands Novartis Investigative Site Groningen
Netherlands Novartis Investigative Site Hardenberg
Netherlands Novartis Investigative Site Heemstede
Netherlands Novartis Investigative Site Heerlen
Netherlands Novartis Investigative Site Leiden
Netherlands Novartis Investigative Site Leiderdorp
Netherlands Novartis Investigative Site Nijmegen
Netherlands Novartis Investigative Site Nijmegen
Netherlands Novartis Investigative Site Sneek The Netherlands
Netherlands Novartis Investigative Site Tiel
Netherlands Novartis Investigative Site Tilburg
Netherlands Novartis Investigative Site Utrecht
Netherlands Novartis Investigative Site Venlo
Netherlands Novartis Investigative Site Zwolle
Norway Novartis Investigative Site Oslo
Norway Novartis Investigative Site Skedsmokorset
Peru Novartis Investigative Site San Miguel Lima
Poland Novartis Investigative Site Bielsko-Biala
Poland Novartis Investigative Site Chrzanow
Poland Novartis Investigative Site Gdansk
Poland Novartis Investigative Site Gdynia
Poland Novartis Investigative Site Kedzierzyn Kozle
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Lodz
Poland Novartis Investigative Site Lodz
Poland Novartis Investigative Site Poznan
Poland Novartis Investigative Site Tarnow Malopolskie
Poland Novartis Investigative Site Warszawa Mazowieckie
Portugal Novartis Investigative Site Coimbra
Portugal Novartis Investigative Site Guimaraes
Portugal Novartis Investigative Site Setubal
Puerto Rico Novartis Investigative Site Ponce
Romania Novartis Investigative Site Baia Mare
Romania Novartis Investigative Site Baia Mare
Romania Novartis Investigative Site Brasov
Romania Novartis Investigative Site Bucharest
Romania Novartis Investigative Site Bucuresti
Romania Novartis Investigative Site Buzau
Romania Novartis Investigative Site Craiova Jud Dolj
Romania Novartis Investigative Site Iasi Jud Iasi
Romania Novartis Investigative Site Iasi
Romania Novartis Investigative Site Timisoara Timis
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Ekaterinburg
Russian Federation Novartis Investigative Site Ekaterinburg
Russian Federation Novartis Investigative Site Ivanovo
Russian Federation Novartis Investigative Site Izhevsk
Russian Federation Novartis Investigative Site Kemerovo
Russian Federation Novartis Investigative Site Kirov
Russian Federation Novartis Investigative Site Korolev Moscow Region
Russian Federation Novartis Investigative Site Krasnodar
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Novosibirsk
Russian Federation Novartis Investigative Site Perm
Russian Federation Novartis Investigative Site Petrozavodsk
Russian Federation Novartis Investigative Site Rostov On Don
Russian Federation Novartis Investigative Site Ryazan
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint-Petersburg
Russian Federation Novartis Investigative Site Samara
Russian Federation Novartis Investigative Site Saratov
Russian Federation Novartis Investigative Site Saratov
Russian Federation Novartis Investigative Site Sochy
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St.- Petersburg
Russian Federation Novartis Investigative Site Tomsk
Russian Federation Novartis Investigative Site Ulyanovsk
Russian Federation Novartis Investigative Site Vsevolozhsk
Russian Federation Novartis Investigative Site Yaroslavl
Russian Federation Novartis Investigative Site Yekaterinburg
Slovakia Novartis Investigative Site Banska Bystrica Slovak Republic
Slovakia Novartis Investigative Site Bardejov
Slovakia Novartis Investigative Site Bardejov
Slovakia Novartis Investigative Site Bardejovske Kupele Bardejov
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Brezno
Slovakia Novartis Investigative Site Dolny Kubin
Slovakia Novartis Investigative Site Handlova SVK
Slovakia Novartis Investigative Site Komarno
Slovakia Novartis Investigative Site Komarno Slovak Republic
Slovakia Novartis Investigative Site Kosice Slovak Republic
Slovakia Novartis Investigative Site Kosice
Slovakia Novartis Investigative Site Lucenec
Slovakia Novartis Investigative Site Nitra
Slovakia Novartis Investigative Site Nitra
Slovakia Novartis Investigative Site Nitra
Slovakia Novartis Investigative Site Nitra Slovak Republic
Slovakia Novartis Investigative Site Nove Zamky
Slovakia Novartis Investigative Site Nove Zamky
Slovakia Novartis Investigative Site Piestany
Slovakia Novartis Investigative Site Povazska Bystrica
Slovakia Novartis Investigative Site Presov
Slovakia Novartis Investigative Site Presov
Slovakia Novartis Investigative Site Rimavska Sobota
Slovakia Novartis Investigative Site Rimavska Sobota Slovak Republic
Slovakia Novartis Investigative Site Roznava Slovak Republic
Slovakia Novartis Investigative Site Svidnik
Slovakia Novartis Investigative Site Trnava
Slovakia Novartis Investigative Site Turcianske Teplice Okr Turcianske Teplice
Slovakia Novartis Investigative Site Zilina Zilinsky Kraj
Slovenia Novartis Investigative Site Ljubljana
South Africa Novartis Investigative Site Cape Town Western Cape
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site George Western Cape
South Africa Novartis Investigative Site Soweto Gauteng
Spain Novartis Investigative Site A Coruna
Spain Novartis Investigative Site Badalona Catalunya
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site Barcelona
Spain Novartis Investigative Site Caceres Extremadura
Spain Novartis Investigative Site Cordoba Andalucia
Spain Novartis Investigative Site Hospitalet de Llobregat Barcelona
Spain Novartis Investigative Site Huelva
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Malaga Andalucia
Spain Novartis Investigative Site Reus Cataluna
Spain Novartis Investigative Site Santander Cantabria
Spain Novartis Investigative Site Santiago de Compostela Galicia
Spain Novartis Investigative Site Sevilla Andalucia
Spain Novartis Investigative Site Sevilla Andalucia
Spain Novartis Investigative Site Sevilla Andalucia
Spain Novartis Investigative Site Valencia Comunidad Valenciana
Spain Novartis Investigative Site Zaragoza
Sweden Novartis Investigative Site Goethenburg
Sweden Novartis Investigative Site Lund
Sweden Novartis Investigative Site Stockholm
Switzerland Novartis Investigative Site Basel
Switzerland Novartis Investigative Site Bern
Switzerland Novartis Investigative Site Geneve 14
Switzerland Novartis Investigative Site Lausanne
Switzerland Novartis Investigative Site Liestal
Switzerland Novartis Investigative Site Zuerich
Taiwan Novartis Investigative Site Hsinchu
Taiwan Novartis Investigative Site Kaohsiung
Taiwan Novartis Investigative Site Kaohsiung
Taiwan Novartis Investigative Site Keelung City
Taiwan Novartis Investigative Site Taichung Taiwan ROC
Taiwan Novartis Investigative Site Tainan
Taiwan Novartis Investigative Site Taipei
Taiwan Novartis Investigative Site Taoyuan
Taiwan Novartis Investigative Site Yilan
Turkey Novartis Investigative Site Ankara Cankaya
Turkey Novartis Investigative Site Haydarpasa Istanbul
Turkey Novartis Investigative Site Istanbul
Turkey Novartis Investigative Site Izmir
Turkey Novartis Investigative Site Izmir
Turkey Novartis Investigative Site Mersin
Turkey Novartis Investigative Site Meselik Eskisehir
Turkey Novartis Investigative Site Samsun
United Kingdom Novartis Investigative Site Birmingham
United Kingdom Novartis Investigative Site Bournemouth
United Kingdom Novartis Investigative Site Bristol
United Kingdom Novartis Investigative Site Cardiff
United Kingdom Novartis Investigative Site Cardiff Wales
United Kingdom Novartis Investigative Site Chertsey Surrey
United Kingdom Novartis Investigative Site Chesterfield
United Kingdom Novartis Investigative Site Chichester West Sussex
United Kingdom Novartis Investigative Site Dorchester Dorset
United Kingdom Novartis Investigative Site Dundee Perthshire
United Kingdom Novartis Investigative Site Edinburgh
United Kingdom Novartis Investigative Site Glasgow
United Kingdom Novartis Investigative Site Harrow
United Kingdom Novartis Investigative Site Leicester
United Kingdom Novartis Investigative Site Liverpool
United Kingdom Novartis Investigative Site London GBR
United Kingdom Novartis Investigative Site London Greater London
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Londonderry
United Kingdom Novartis Investigative Site Manchester
United Kingdom Novartis Investigative Site Middlesbrough
United Kingdom Novartis Investigative Site Middlesex
United Kingdom Novartis Investigative Site Newcastle upon Tyne
United Kingdom Novartis Investigative Site Newport
United Kingdom Novartis Investigative Site Norwich
United Kingdom Novartis Investigative Site Plymouth
United Kingdom Novartis Investigative Site Portadown Nothern Ireland
United Kingdom Novartis Investigative Site Preston Lancashire
United Kingdom Novartis Investigative Site Rhyl Wales
United Kingdom Novartis Investigative Site Rochdale North Manchester
United Kingdom Novartis Investigative Site Sheffield
United Kingdom Novartis Investigative Site Sketty Swansea
United Kingdom Novartis Investigative Site Stockton on Tees Cleveland
United Kingdom Novartis Investigative Site Sunderland Tyne And Wear
United Kingdom Novartis Investigative Site Taunton Somerset
United Kingdom Novartis Investigative Site Tyne And Wear
United Kingdom Novartis Investigative Site West Midlands
United Kingdom Novartis Investigative Site Wiltshire
United Kingdom Novartis Investigative Site Wrexham
United States Novartis Investigative Site Akron Ohio
United States Novartis Investigative Site Akron Ohio
United States Novartis Investigative Site Albany New York
United States Novartis Investigative Site Alexandria Louisiana
United States Novartis Investigative Site Andalusia Alabama
United States Novartis Investigative Site Atlanta Georgia
United States Novartis Investigative Site Atlanta Georgia
United States Novartis Investigative Site Atlanta Georgia
United States Novartis Investigative Site Atlanta Georgia
United States Novartis Investigative Site Aurora Colorado
United States Novartis Investigative Site Baltimore Maryland
United States Novartis Investigative Site Baltimore Maryland
United States Novartis Investigative Site Baltimore Maryland
United States Novartis Investigative Site Baton Rouge Louisiana
United States Novartis Investigative Site Belzoni Mississippi
United States Novartis Investigative Site Beverly Hills California
United States Novartis Investigative Site Beverly Hills California
United States Novartis Investigative Site Birmingham Alabama
United States Novartis Investigative Site Boca Raton Florida
United States Novartis Investigative Site Bogalusa Louisiana
United States Novartis Investigative Site Bossier City Louisiana
United States Novartis Investigative Site Boston Massachusetts
United States Novartis Investigative Site Boston Massachusetts
United States Novartis Investigative Site Bountiful Utah
United States Novartis Investigative Site Bradenton Florida
United States Novartis Investigative Site Brandon Florida
United States Novartis Investigative Site Bridgeport Connecticut
United States Novartis Investigative Site Canton Ohio
United States Novartis Investigative Site Charlotte North Carolina
United States Novartis Investigative Site Chicago Illinois
United States Novartis Investigative Site Cincinnati Ohio
United States Novartis Investigative Site Cincinnati Ohio
United States Novartis Investigative Site Cincinnati Ohio
United States Novartis Investigative Site Cleveland Ohio
United States Novartis Investigative Site Columbia Maryland
United States Novartis Investigative Site Columbus Ohio
United States Novartis Investigative Site Cottonwood Arizona
United States Novartis Investigative Site Covina California
United States Novartis Investigative Site Covington Louisiana
United States Novartis Investigative Site Dallas Texas
United States Novartis Investigative Site Dallas Texas
United States Novartis Investigative Site Dallas Texas
United States Novartis Investigative Site Dallas Texas
United States Novartis Investigative Site Danville Virginia
United States Novartis Investigative Site Detroit Michigan
United States Novartis Investigative Site Detroit Michigan
United States Novartis Investigative Site Dunwoody Georgia
United States Novartis Investigative Site Eunice Louisiana
United States Novartis Investigative Site Falls Church Virginia
United States Novartis Investigative Site Flint Michigan
United States Novartis Investigative Site Fort Lauderdale Florida
United States Novartis Investigative Site Fort Mill South Carolina
United States Novartis Investigative Site Fort Washington Maryland
United States Novartis Investigative Site Germantown Tennessee
United States Novartis Investigative Site Gilbert Arizona
United States Novartis Investigative Site Grand Blanc Michigan
United States Novartis Investigative Site Greensboro North Carolina
United States Novartis Investigative Site Greensboro North Carolina
United States Novartis Investigative Site Hammond Louisiana
United States Novartis Investigative Site Hartford Connecticut
United States Novartis Investigative Site High Point North Carolina
United States Novartis Investigative Site Houma Louisiana
United States Novartis Investigative Site Houston Texas
United States Novartis Investigative Site Huntington Beach California
United States Novartis Investigative Site Huntsville Alabama
United States Novartis Investigative Site Indianapolis Indiana
United States Novartis Investigative Site Iowa City Iowa
United States Novartis Investigative Site Jackson Tennessee
United States Novartis Investigative Site Jacksonville Florida
United States Novartis Investigative Site Jacksonville Florida
United States Novartis Investigative Site Jacksonville Florida
United States Novartis Investigative Site Kalamazoo Michigan
United States Novartis Investigative Site Kansas City Kansas
United States Novartis Investigative Site Knoxville Tennessee
United States Novartis Investigative Site La Jolla California
United States Novartis Investigative Site Lafayette Louisiana
United States Novartis Investigative Site Lancaster Pennsylvania
United States Novartis Investigative Site Layton Utah
United States Novartis Investigative Site Lebanon New Hampshire
United States Novartis Investigative Site Lincoln Nebraska
United States Novartis Investigative Site Little Rock Arkansas
United States Novartis Investigative Site Livingston Texas
United States Novartis Investigative Site Long Beach California
United States Novartis Investigative Site Los Angeles California
United States Novartis Investigative Site Los Angeles California
United States Novartis Investigative Site Manassas Virginia
United States Novartis Investigative Site Manhasset New York
United States Novartis Investigative Site Maplewood Minnesota
United States Novartis Investigative Site Marion Ohio
United States Novartis Investigative Site Marshall Texas
United States Novartis Investigative Site Metairie Louisiana
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site Milwaukee Wisconsin
United States Novartis Investigative Site Minneapolis Minnesota
United States Novartis Investigative Site Minneapolis Minnesota
United States Novartis Investigative Site Mobile Alabama
United States Novartis Investigative Site Morgantown West Virginia
United States Novartis Investigative Site Murray Utah
United States Novartis Investigative Site Naples Florida
United States Novartis Investigative Site Nashville Tennessee
United States Novartis Investigative Site New Orleans Louisiana
United States Novartis Investigative Site New Orleans Louisiana
United States Novartis Investigative Site New York New York
United States Novartis Investigative Site New York New York
United States Novartis Investigative Site New York New York
United States Novartis Investigative Site New York New York
United States Novartis Investigative Site New York New York
United States Novartis Investigative Site Norfolk Virginia
United States Novartis Investigative Site Northridge California
United States Novartis Investigative Site Omaha Nebraska
United States Novartis Investigative Site Omaha Nebraska
United States Novartis Investigative Site Opelousas Louisiana
United States Novartis Investigative Site Orange California
United States Novartis Investigative Site Park Ridge Illinois
United States Novartis Investigative Site Petoskey Michigan
United States Novartis Investigative Site Philadelphia Pennsylvania
United States Novartis Investigative Site Pittsburgh Pennsylvania
United States Novartis Investigative Site Port Charlotte Florida
United States Novartis Investigative Site Port Orange Florida
United States Novartis Investigative Site Portland Oregon
United States Novartis Investigative Site Powell Tennessee
United States Novartis Investigative Site Providence Rhode Island
United States Novartis Investigative Site Raleigh North Carolina
United States Novartis Investigative Site Rapid City South Dakota
United States Novartis Investigative Site Richmond Virginia
United States Novartis Investigative Site Ridgewood New Jersey
United States Novartis Investigative Site Rochester New York
United States Novartis Investigative Site Rochester New York
United States Novartis Investigative Site Rockville Maryland
United States Novartis Investigative Site Saginaw Michigan
United States Novartis Investigative Site Saint Augustine Florida
United States Novartis Investigative Site Saint Louis Missouri
United States Novartis Investigative Site Saint Louis Missouri
United States Novartis Investigative Site Saint Louis Missouri
United States Novartis Investigative Site Saint Peters Missouri
United States Novartis Investigative Site Salt Lake City Utah
United States Novartis Investigative Site San Diego California
United States Novartis Investigative Site San Francisco California
United States Novartis Investigative Site San Francisco California
United States Novartis Investigative Site Sanford North Carolina
United States Novartis Investigative Site Santa Ana California
United States Novartis Investigative Site Scarborough Maine
United States Novartis Investigative Site Seattle Washington
United States Novartis Investigative Site Seattle Washington
United States Novartis Investigative Site Seattle Washington
United States Novartis Investigative Site Shelby North Carolina
United States Novartis Investigative Site Shreveport Louisiana
United States Novartis Investigative Site Shreveport Louisiana
United States Novartis Investigative Site Slidell Louisiana
United States Novartis Investigative Site Southampton New York
United States Novartis Investigative Site Southaven Mississippi
United States Novartis Investigative Site Stanford California
United States Novartis Investigative Site Stockton California
United States Novartis Investigative Site Summerville South Carolina
United States Novartis Investigative Site Summit New Jersey
United States Novartis Investigative Site Sun City West Arizona
United States Novartis Investigative Site Temple Texas
United States Novartis Investigative Site Thomasville Georgia
United States Novartis Investigative Site Tomball Texas
United States Novartis Investigative Site Topeka Kansas
United States Novartis Investigative Site Tucson Arizona
United States Novartis Investigative Site Waterbury Connecticut
United States Novartis Investigative Site Wellington Florida
United States Novartis Investigative Site West Hills California
United States Novartis Investigative Site Winston-Salem North Carolina
United States Novartis Investigative Site Wyoming Michigan
United States Novartis Investigative Site Yardley Pennsylvania
United States Novartis Investigative Site Yazoo City Mississippi
United States Novartis Investigative Site Zachary Louisiana

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Bulgaria,  Canada,  Chile,  China,  Colombia,  Czechia,  Denmark,  France,  Germany,  Greece,  Guatemala,  Hong Kong,  Hungary,  Iceland,  India,  Israel,  Italy,  Japan,  Korea, Republic of,  Mexico,  Netherlands,  Norway,  Peru,  Poland,  Portugal,  Puerto Rico,  Romania,  Russian Federation,  Slovakia,  Slovenia,  South Africa,  Spain,  Sweden,  Switzerland,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to first occurrence of clinical endpoint committee confirmed expanded major adverse cardiovascular events in patients with elevated Lp(a) = 70 mg/dL Demonstrate the superiority of pelacarsen (TQJ230) compared to placebo in reducing the risk of expanded MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization requiring hospitalization) in the overall study population with established CVD and (Lp(a) = 70 mg/dL) approximately 4 years
Primary Time to the first occurrence of clinical endpoint committee confirmed expanded major adverse cardiovascular events in a population of patients with elevated Lp(a) = 90 mg/dL. Demonstrate the superiority of pelacarsen (TQJ230) compared to placebo in reducing the risk of expanded MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization requiring hospitalization) in the overall study population with established CVD and (Lp(a) = 90 mg/dL) approximately 4 years
Secondary Time to the first occurrence of the clinical endpoint committee confirmed composite endpoint of major adverse cardiovascular events (CV death, non-fatal MI, and non-fatal stroke) Demonstrate the superiority of pelacarsen (TQJ230) compared to placebo in reducing the risk of the MACE composite of CV death, nonfatal MI and non-fatal stroke. approximately 4 years
Secondary Time to the first occurrence of the clinical endpoint committee confirmed composite endpoint of coronary heart disease: coronary heart disease death, non-fatal MI, urgent coronary re-vascularization requiring hospitalization Demonstrate the superiority of pelacarsen (TQJ230) compared to placebo in reducing the risk of the composite of coronary heart disease (CHD) outcomes: death due to CHD, nonfatal MI and urgent coronary revascularization requiring hospitalization. approximately 4 years
Secondary Number of participants with confirmed all-cause death Evaluation by clinical endpoint committee the rate of all-cause death approximately 4 years
See also
  Status Clinical Trial Phase
Completed NCT03887520 - Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) N/A